ABBOTT LABORATORIES Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax
ABBOTT LABORATORIES (ABT) reported Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax of $26.00 million for the 3-month period ending 2019-06-30, per its 10-Q filed 2019-07-31.
Discontinued › Notes › Equity › AOCI Including Portion Attributable to Noncontrolling Interest
us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax · last filed 2019-07-31
- ABBOTT LABORATORIES reclassification from accumulated other comprehensive income, current period, before tax for the quarter ending 2019-06-30 was $26.00M.
- ABBOTT LABORATORIES reclassification from accumulated other comprehensive income, current period, before tax for the quarter ending 2018-06-30 was -$2.00M.
| Period end | Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax 3 month | Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax 6 month |
|---|---|---|
| 2019-06-30 | $26.00M 10-Q · filed 2019-07-31 | $75.00M 10-Q · filed 2019-07-31 |
| 2018-06-30 | -$2.00M 10-Q · filed 2019-07-31 | -$50.00M 10-Q · filed 2019-07-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |